Replies to post #206317 on Avid Bioservices Inc (CDMO)

[md1225]

Have you forgotten that bavituximab actually more then doubled survival in 2nd line lung cancer (110% improvement in mos), and the FDA set the bar on the SUNRISE trial so low (25% improvement in mos) and has Fast Track status?

This 25% improvement MUST be showing today for the bavituximab group imo and its only a matter of short time till SUNRISE is halted. By FDA protocol the trial can only be halted IF Peregrine has the ability to commercialize bavituximab. Avid build out should be done by summer.

First look-in anytime after that imo.